drugset / Trial / NCT06283121
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
Phase 2
Not yet recruiting
30 enrolled
China Medical University, China
Beijing Bio-Targeting Therapeutics Technology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.
Timeline
- Start
- 2024-04-02
- Primary completion
- 2027-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BioTTT001 | Unknown | 1e+10 unknown | Other |
| Subject | Oxaliplatin | Small molecule | 130 mg | Intravenous |
| Subject | S-1 | Small molecule | 40 mg | Oral |
| Subject | S-1 | Small molecule | 60 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 160 mg | Intravenous |